India Orders Post-Marketing Data For Pfizer’s Champix
This article was originally published in PharmAsia News
Executive Summary
India's drug regulator has instructed U.S. drug maker Pfizer's Indian subsidiary to submit post-marketing data on the impact of its Champix (varenicline) drug to help smokers quit. Although Indian physicians have not reported seeing problems with use of the psychotropic drug, Pfizer was instructed to complete its post-marketing study by May of next year, followed by regular updates. A Pfizer Ltd. official said the study already is underway with 300 patients at 21 sites. India's post-marketing surveillance regulations usually are followed only if the government specifically orders them. (Click here for more
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.